Vantage logo

Why Novo Nordisk should buy Uniqure

Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.

Vantage logo

A ternary outcome for Tocagen

Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.